hodgkin’s lymphoma

© Cancer Research UK 2005 Registered charity number 1089464

Hodgkin’s Lymphoma

The statistics in this presentation are based on the Cervical CancerStats report published in 2007. However, the incidence, mortality and survival statistics have been updated to reflect the latest available data.

For more information about UK cancer statistics please contact [email protected] or visit http://info.cancerresearchuk.org/cancerstats


Figure One: The lymphatic system showing sites commonly affected by Hodgkin's lymphoma


Table One: Number of new cases and rates of Hodgkin's lymphoma, UK, 2006

England Wales Scotland N.Ireland UK

Cases

Males 744 39 80 22 885

Females 607 30 67 22 726

Persons 1,351 69 147 44 1,611

Crude rate per 100,000 population

Males 3.0 2.7 3.2 2.6 3.0

Females 2.3 2.0 2.5 2.5 2.4

Persons 2.7 2.3 2.9 2.5 2.7

Age-standardised rate (European) per 100,000 population

Males 2.9 2.4 3.1 2.5 2.995% CI 2.7 3.1 1.7 3.2 2.4 3.7 1.5 3.5 2.7 3.1

Females 2.2 2.0 2.4 2.4 2.295% CI 2.0 2.3 1.3 2.7 1.9 3.0 1.4 3.4 2.0 2.3

Persons 2.5 2.2 2.7 2.5 2.595% CI 2.4 2.7 1.7 2.7 2.3 3.2 1.7 3.2 2.4 2.7


Figure Two: Numbers of new cases and age specific incidence rates, by sex, Hodgkin's lymphoma, UK 2006


Figure Three: Incidence of Nodular Sclerosis and Mixed Cellularity subtypes of Hodgkin's lymphoma by age and sex, England, 1995-2001


Figure Four: Age-standardised* (European) incidence rates, Hodgkin's lymphoma, by sex, Great Britain, 1975-2006

* to the European standard population


Figure Five: Age-standardised* incidence and mortality rates for Hodgkin's lymphoma in males, selected EU countries, 2000 estimates



Figure Six: Proportion of EBV-associated Hodgkin's lymphoma cases by age group


Table Two: Summary of Ann Arbor staging system

Stage Description

Stage I disease in single lymph node region

Stage II disease in 2 or more regions on the same side of the diaphragm

Stage III disease in lymph node regions on both sides of the diaphragm

Stage IV diffuse or disseminated disease in one or more extralymphatic sites (e.g. liver

and bone marrow) with or without lymph node involvement


Table Three: Prognostic groups in early stage HD (EORTC)

Group Prognostic factors

very favourable stage I and age <40 and 'A' + ESR <50 + female and MT ratio* <0.35

favourable all other patients

unfavourable age ≥50, or 'A' + ESR ≥50, or 'B' + ESR ≥30, or stage II4/5$

, or MT ratio

≥0.35

*MT ratio = size of mediastinal mass compared with transverse diameter of chest on chest X-ray

$ the subscript number denotes the number of nodal regions involved - an adverse prognostic factor

ESR = erythrocyte sedimentation rate


Table Four: Adverse prognostic factors in advanced HD according to the International Prognostic Factors Project

Hb < 10.5g/l white cell count >16 x 109/l

male gender lymphocytopenia <0.6 x 109/l or < 8% of total white cell count

stage IV albumin <4g/l

age 45 years


Figure Seven: Tumour control rates according to number of risk factors from the International Prognostic Factors Project on Advanced Hodgkin's lymphoma


Figure Eight: Age-standardised* relative survival by sex, for patients diagnosed with Hodgkin's lymphoma, England & Wales, 1971-75 to 1996-99



Table Five: Numbers of deaths and rates of Hodgkin's lymphoma, UK by sex and country, 2003


Figure Nine: Relative survival by sex and age group, for patients diagnosed with Hodgkin's lymphoma, England & Wales, 1996-1999


Figure Ten: Number of deaths and age-specific mortality rates, Hodgkin's lymphoma, by sex, UK, 2007


Figure Eleven: Age-standardised* (European) mortality, by sex, Hodgkin's lymphoma, United Kingdom, 1971-2007


hodgkin’s lymphoma

Documents